| Fungal Infection |
1 |
1 |
| Skin and Soft Tissue Infection |
0 |
0.95 |
| Candidiasis |
0 |
0.97 |
| Vulvovaginal Candidiasis |
0 |
0.99 |
| Vaginal Candidiasis |
0 |
0.98 |
| Pregnancy |
0 |
0.39 |
| Antifungal |
0 |
0.95 |
| Health Care Reform |
0 |
0.24 |
| Liver |
0 |
0.24 |
| Outpatient Clinic |
0 |
0.24 |
| Congenital Anomaly |
0 |
0.17 |
| Adverse Effects |
0 |
0.12 |
| Birth |
0 |
0.12 |
| Candida |
0 |
0.12 |
| Clinical Guidelines |
0 |
0.12 |
| Drug Interaction |
0 |
0.12 |
| Face |
0 |
0.12 |
| Food and Drug Administration (FDA) |
0 |
0.12 |
| Health Care Economics |
0 |
0.12 |
| Match |
0 |
0.12 |
| Medical Life |
0 |
0.12 |
| Patient Safety |
0 |
0.12 |
| Psychosocial |
0 |
0.12 |
| Social Determinants of Health |
0 |
0.12 |
| Spontaneous Abortion |
0 |
0.12 |
| Toxicology |
0 |
0.12 |
| Vagina |
0 |
0.12 |
| Vaginitis |
0 |
0.12 |